TB-500

• Good comparator for systemic recovery logic.
• Relevant if the issue feels broader than a single local pain point.
• Helps educate against blend-first thinking.

• Less precise fit than BPC-157 for Ana's patellar tendinopathy.
• Research-only and anti-doping context must be visible.
• Not a substitute for rehab progression.

• Local irritation or nonspecific symptoms may be reported in research-use contexts.
• Attribution is difficult when paired with BPC-157.
• Quality and identity uncertainty are central risks.

• FDA safety-risk concerns for thymosin beta-4 fragment products.
• Anti-doping rules may apply to thymosin beta-4 derivatives.
• Cancer, active infection, surgery, pregnancy, and unexplained injury need professional review.

• Competitive sport without anti-doping review.
• Active malignancy or unresolved oncology history without clinician review.
• Active infection, open wound complication, or recent surgery without clinical direction.
• Pregnancy or lactation without professional review.
• Acute trauma with severe pain, inability to bear weight, suspected rupture, deformity, fever, heat, redness, discharge, neurologic symptoms, progressive night pain, suspected fracture, post-operative worsening, or unexplained worsening despite rest.

• Whether the recovery question is local tendon pain, systemic training recovery, or soft-tissue remodeling.
• The level of sport-rule review needed for tested athletes.
• How clinicians weigh animal, ocular, dermal, and fragment literature.

• Identity distinction between full-length thymosin beta-4 and TB-500 fragment products.
• FDA safety-risk concerns around immunogenicity, peptide-related impurities, and lack of human exposure data for the fragment.
• Anti-doping status for competitive athletes.
• Treating loading/maintenance community language as an official protocol.
• Using blends when causality matters.

TB-500 administration language is especially vulnerable to community-protocol drift. This dossier avoids translating fragment research into application instructions.

• Verify identity before interpreting mechanism or evidence.
• Do not use vendor shorthand as proof that the product matches a studied molecule.
• Avoid blending with BPC-157 when evaluating response clarity.
• Tested athletes need sport-rule review before any practical discussion.

The maintenance question is whether function and rehab capacity improve, not whether a community loading phase was completed.

• Keep progressive loading and symptom tracking as the reference frame.
• If multiple compounds are layered, attribution becomes weak.
• If the target is chronic pain without diagnosis, reassess before adding mechanisms.

• Thymosin beta-4 biology has meaningful repair literature.
• TB-500 fragment-specific human recovery evidence is less mature.
• Identity and regulation are part of the evidence interpretation.

• Research-only products should not be treated as equivalent to studied or approved medication.
• Blends add quality and attribution risk.
• Anti-doping context may make practical use inappropriate for tested athletes.

• Rehab, progressive load, sleep, and nutrition remain the cleanest support foundation.
• BPC-157 pairing can be discussed conceptually in the final map.
• Identity verification is a prerequisite before any combination interpretation.

• TB-500 plus unknown thymosin fragments.
• TB-500 inside all-in-one blends with no component clarity.
• Multiple repair peptides added before the injury driver is clear.

• Tested athletes.
• Surgery, active infection, malignancy history, pregnancy, or severe injury.
• Any multi-peptide blend decision.

• Frequently discussed with BPC-157 for tendon, ligament, and training recovery.
• Users often describe systemic recovery or mobility themes.
• Vendor naming confusion appears often.

• Anti-doping concerns.
• Unclear fragment identity.
• No clean attribution inside a blend.
• Limited human evidence.

• Community use explains why TB-500 belongs in the map.
• It does not establish a clinical protocol.
• Identity clarity is the first filter.